Afuresertib

DRUG7 trials

Sponsors

Novartis Pharmaceuticals, Novartis, GlaxoSmithKline, Laekna Limited

Conditions

Breast CancerCancerCervical CancerEndometrial CancerEsophageal CancerGastric and Gastroesophageal Junction AdenocarcinomaNSCLCNeoplasms, Haematologic

Phase 1

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

TerminatedNCT02177682

Novartis PharmaceuticalsNeoplasms, Haematologic

Start: 2014-08-13End: 2019-08-14Updated: 2021-08-11

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

TerminatedNCT02235740

Start: 2014-11-30End: 2015-10-31Updated: 2016-05-04

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

CompletedNCT02240212

Novartis PharmaceuticalsCancer

Start: 2014-10-31End: 2017-02-07Updated: 2017-04-11

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

WithdrawnNCT02380313

GlaxoSmithKlineCancer

Start: 2015-10-31End: 2017-05-31Updated: 2016-10-06

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

CompletedNCT05383482

Laekna LimitedCervical Cancer, Endometrial Cancer, Esophageal Cancer +3

Start: 2022-07-01End: 2024-07-18Updated: 2025-11-17

Phase 2

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

CompletedNCT04374630

Laekna LimitedPlatinum-resistant Ovarian Cancer

Start: 2020-06-09End: 2024-06-28Updated: 2025-09-10

Phase 3

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Active, not recruitingNCT04851613

Laekna LimitedBreast Cancer

Start: 2022-02-18End: 2026-12-30Target: 256Updated: 2026-04-02

Related Papers

An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).

2025-03-011 citations

Abstract PS17-08: A Phase Ib Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies

Cancer Research2024-05-02

180 An open-label randomized active-controlled phase ii clinical study to assess efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer

Poster2020-11-01